Acceleron to Participate at the Morgan Stanley 2009 Global Healthcare Unplugged Conference

CAMBRIDGE, Mass. – September 10, 2009 –Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle and the vasculature today announced that it will participate as one of only a few private companies at the 2009 Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009. The conference will be held at the Grand Hyatt Hotel in New York City.

About Acceleron

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers of the TGF-beta superfamily of proteins. ACE-011 is currently being studied in two Phase 2 clinical trials in cancer patients. ACE-031 is currently being studied in a Phase 1 multiple dose clinical trial. In addition, the company is advancing new product candidates that increase muscle mass, control angiogenesis, inhibit fat accumulation and increase hemoglobin. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron include Advanced Technology Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For more information, visit www.acceleronpharma.com.

CONTACT:

Acceleron Pharma:
Steven Ertel, 617-649-9234
Vice President, Corporate Development

Mariesa Kemble (Media)
Suda Communications LLC, 608-850-4745

BACK TO PRESS RELEASES